Afya Dividendi e riacquisti
Criteri Dividendo verificati 4/6
Afya è una società che paga dividendi con un rendimento attuale pari a 5.03%, ben coperto dagli utili.
Informazioni chiave
5.0%
Rendimento del dividendo
0.8%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | 5.8% |
| Rendimento futuro dei dividendi | 10.3% |
| Crescita dei dividendi | n/a |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | 41% |
Aggiornamenti recenti su dividendi e riacquisti
Recent updates
Aggiornamento dell'analisi • May 05
AFYA: Future Margin Discipline And Non Core Investments Will Drive Re Rating
Afya's updated analyst price target has edged to about $20.90 from roughly $20.70, as analysts factor in higher modeled revenue growth and profit margins alongside a lower assumed future P/E. They are also weighing recent price target cuts and downgrades tied to rising investments in non-core businesses and a slower ramp-up in medical practice solutions.Aggiornamento dell'analisi • Apr 20
AFYA: Future Margin Discipline And Dividend Payouts Will Drive Re Rating
Afya's analyst price target has moved from $22 to $17, as analysts respond to rising investments in non core businesses and a slower than expected ramp up in medical practice solutions. This also feeds into more conservative assumptions on fair value, profit margins and future P/E multiples.
Aggiornamento dell'analisi • Apr 06
AFYA: Non Core Investments And Dividends Will Shape A More Balanced Outlook
The updated analyst price target on Afya edges up slightly to about $15.87 from $15.80, as analysts factor in a lower discount rate and a modestly higher margin outlook, while also acknowledging recent sector downgrades and concerns around the pace of returns from newer business lines. Analyst Commentary Recent Street research highlights a clear shift toward caution on Afya, with several Bearish analysts recalibrating expectations for both the core education business and newer service lines.
Aggiornamento dell'analisi • Mar 23
AFYA: Recent Downgrades Will Set Up Longer-Term Upside From Core Operations
Narrative Update on Afya The analyst price target for Afya is now aligned with a fair value estimate of about $17.14, down from $17.95, as analysts factor in softer revenue growth assumptions, slightly lower future P/E expectations, and higher perceived risk tied to increased investments in non core businesses and a longer ramp up in medical practice solutions. Analyst Commentary Recent research on Afya has shifted toward a more cautious stance, with several downgrades and trims to price targets as analysts reassess the balance between growth projects and near term returns.Aggiornamento dell'analisi • Mar 09
AFYA: Non Core Investments Will Set Up Future Shareholder Upside
Afya's updated analyst price target edges up to about $15.80 from roughly $15.73, as analysts factor in a mix of slightly higher modeled revenue growth and modestly lower profit margins, along with Street research pointing to near term pressure from increased investment in non core businesses and a slower buildout of medical practice solutions. Analyst Commentary Recent Street research leans cautious on Afya, with several bearish analysts revisiting their ratings and fair value assumptions.Aggiornamento dell'analisi • Feb 22
AFYA: Recent Rating Cuts Will Set Up Medium-Term Revaluation Opportunity
Afya's analyst price target has been trimmed by $0.01 to $17.95 as analysts factor in slightly higher assumed revenue growth, a lower discount rate, and a reduced profit margin outlook, in line with the recent wave of downgrades and target cuts across the Street. Analyst Commentary Recent Street research around Afya has turned more cautious, with several downgrades and modest target cuts clustering over a short period.Articolo di analisi • Feb 10
There's Been No Shortage Of Growth Recently For Afya's (NASDAQ:AFYA) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...Aggiornamento dell'analisi • Feb 08
AFYA: Recalibrated Street Views Will Highlight Earnings Guidance And Share Buyback Potential
Afya's updated analyst price target has shifted from about US$25.62 to about US$22.95. Analysts cite more cautious assumptions around revenue growth and profit margins, which are partly reflected in recent target cuts and downgrades from several firms.Aggiornamento dell'analisi • Jan 24
AFYA: Share Repurchases And Reaffirmed 2025 Guidance Will Support Medium-Term Outlook
Afya's analyst fair value estimate edged down from about $18.53 to $17.96 as analysts trimmed long term assumptions and lowered price targets following a series of recent downgrades and updated sector views. Analyst Commentary Recent Street research on Afya has turned more cautious, with several price target cuts and rating downgrades feeding into the lower fair value estimate.Aggiornamento dell'analisi • Jan 09
AFYA: Share Repurchases And Guidance Will Offset Softer Sector Enthusiasm
Afya's analyst price target has been revised slightly lower, with recent cuts to US$18 and US$22 from prior targets of US$19 and US$24.50, as analysts factor in updated estimates for Brazil education peers and Afya's comparatively smaller benefit from the local easing cycle. Analyst Commentary Recent Street research on Afya has tilted more cautious, with price targets adjusted lower and one major bank stepping back from a more bullish stance.Aggiornamento dell'analisi • Dec 23
AFYA: Share Buybacks And Guidance Will Support Steady Prospects Ahead
Analysts have raised their price target on Afya by approximately 8 percent to about R$15.60 from roughly R$14.40. This change reflects expectations of slightly faster revenue growth and a modestly lower discount rate, partially offset by a leaner profit margin outlook and a higher assumed future P/E multiple.Aggiornamento dell'analisi • Dec 09
AFYA: Preferred Share Buyback Will Support Medium-Term Earnings Outlook
Analysts have modestly trimmed their price target on Afya, reducing fair value by approximately 1 percent to about $18.53. This reflects expectations for slower revenue growth and slightly lower profit margins, partly offset by a higher assumed future P/E multiple.Seeking Alpha • Dec 01
Afya's 3Q25 And Investor Day Provide More Data On Undergraduate Competition Increasing
Summary Afya (AFYA) faces mounting competition and regulatory risks in its core undergraduate medical education segment, which comprises the majority of its business. AFYA's efforts to offset undergraduate challenges with graduate education and digital ecosystem offerings remain too small and lower-margin to drive significant growth. The company trades at under 10x expected cash flows, has low leverage, and announced a 4% share repurchase program, signaling a potential shift toward capital returns. Despite a seemingly cheap valuation, I maintain a Hold rating due to persistent concerns about margin pressure and growth sustainability in AFYA's main segment. Read the full article on Seeking AlphaAggiornamento dell'analisi • Oct 12
Brazil Medical Education And Digital Trends Will Secure Future Opportunity
Analysts have slightly lowered their price target for Afya from $19.30 to $18.78, citing sector-wide regulatory changes and a narrowed valuation gap compared to industry peers. Analyst Commentary Recent analyst updates reflect a nuanced view of Afya’s prospects, balancing optimism regarding its near-term outlook with tempered expectations due to evolving sector dynamics.Articolo di analisi • Sep 30
Here's Why Afya (NASDAQ:AFYA) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Sep 12
Investors Will Want Afya's (NASDAQ:AFYA) Growth In ROCE To Persist
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Articolo di analisi • Jul 26
Afya Limited's (NASDAQ:AFYA) Subdued P/E Might Signal An Opportunity
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Articolo di analisi • Jun 15
Is Now The Time To Put Afya (NASDAQ:AFYA) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • May 30
Is Afya (NASDAQ:AFYA) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • May 11
Earnings Beat: Afya Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for Afya Limited ( NASDAQ:AFYA ) shareholders, because the company has just released its latest...Articolo di analisi • Apr 28
The Return Trends At Afya (NASDAQ:AFYA) Look Promising
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Articolo di analisi • Feb 27
We Think Afya (NASDAQ:AFYA) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Nuova analisi • Jan 23
AFYA Market Outlook
Laureate Education (NASDAQ: LAUR): An international network of campus-based and online universities, Laureate offers undergraduate and postgraduate degree programs globally, including in Latin AmericaArticolo di analisi • Jan 16
Is There An Opportunity With Afya Limited's (NASDAQ:AFYA) 48% Undervaluation?
Key Insights Afya's estimated fair value is US$29.81 based on 2 Stage Free Cash Flow to Equity Afya's US$15.64 share...Articolo di analisi • Dec 13
Should You Be Adding Afya (NASDAQ:AFYA) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 30
Afya Continues To Be An Opportunity Even After Brazil's Depreciation
Summary Afya's 3Q24 results showed 12% organic revenue growth and 16% overall growth, driven by the Unidom acquisition and strong performance in medical education and software segments. The company leveraged its cost structure, achieving a 300bps increase in adj EBITDA margin and a 68% YoY net income growth despite higher financial costs. Afya's valuation remains attractive, with a P/E of 11x and a potential yield of 20% in a few years, justifying a Buy rating. Despite country-level challenges, Afya's growth potential and strategic capital allocation make it a compelling investment opportunity. Read the full article on Seeking Alpha
Nuova analisi • Nov 21
Expanding Medical Practice Solutions And Tactical Acquisitions Fuel Robust Revenue Growth
Strategic acquisitions and expansion in medical practice solutions are expected to enhance revenue, profitability, and operational efficiency.Articolo di analisi • Nov 17
Afya (NASDAQ:AFYA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Nov 03
Investors Holding Back On Afya Limited (NASDAQ:AFYA)
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...Articolo di analisi • Oct 18
Returns At Afya (NASDAQ:AFYA) Are On The Way Up
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Seeking Alpha • Aug 29
Afya: Q2 2024 Was Not Surprising, Still An Opportunity Despite New Info On Market Supply
Summary Afya's Q2 2024 results showed stable operations with 14% revenue growth, driven by increased enrollment and tuition, and improved operating margins. A favorable Supreme Court ruling on medical seat openings and new financing from the IFC are positive developments for Afya. Despite short-term stability, long-term concerns arise due to potential oversupply in Brazil's medical education and profession markets. Financial expenses decreased due to a 20% reduction in net debt and lower Brazilian interbank rates, enhancing Afya's financial position. Read the full article on Seeking AlphaArticolo di analisi • Aug 29
Here's Why Afya (NASDAQ:AFYA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Aug 15
Is It Time To Consider Buying Afya Limited (NASDAQ:AFYA)?
While Afya Limited ( NASDAQ:AFYA ) might not have the largest market cap around , it saw a decent share price growth of...Articolo di analisi • Jul 17
Afya (NASDAQ:AFYA) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Jun 20
Afya Limited (NASDAQ:AFYA) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Afya is US$30.02 based on 2 Stage Free Cash Flow to Equity Afya's US$17.24...Seeking Alpha • Jun 06
Afya's Results Are Improving And The Market Is Undervaluing It
Summary Afya Limited reports strong 1Q24 results with revenue up 13%, adjusted EBITDA up 20%, and net income up 77%. The company increases its total approved seats to 2,500 through acquisitions and organic growth. Afya's valuation becomes more attractive as the stock price decreases, trading at an EV/NOPAT ratio of 11x. Read the full article on Seeking AlphaArticolo di analisi • May 14
Do Afya's (NASDAQ:AFYA) Earnings Warrant Your Attention?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Seeking Alpha • Apr 29
AFYA: Mr Market Is Mistaken
Summary The company's 2023 earnings and revenue were strong, but its stock price has declined significantly. The selloff is largely due to AFYA's declining revenue growth rates. Guidance is also soft, adding to concerns from investors and analysts. However, AFYA's business model is not broken and the market's overreaction provides a wide margin of safety to invest in a profitable company with a dominant position. Investors who can readjust their expectations to see AFYA in a different light will see that AFYA is a strong and growing business that is selling at a discount. Read the full article on Seeking AlphaArticolo di analisi • Apr 27
Is Now The Time To Look At Buying Afya Limited (NASDAQ:AFYA)?
Afya Limited ( NASDAQ:AFYA ), is not the largest company out there, but it saw a decent share price growth of 12% on...Articolo di analisi • Apr 09
Afya (NASDAQ:AFYA) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Mar 19
Afya Is Performing Well And Is A Buy
Summary Afya is one of the leading private medical education providers in Brazil. The company's model has several quality characteristics including high pricing power, and resiliency to economic cycles. Afya has a significant runway to grow organically and inorganically, via seat expansions, price adjustments and acquisitions. The current stock price represents a low multiple of FY24E free cash flow adjusted for CAPEX. This leaves most growth potential as additional upside. Read the full article on Seeking AlphaArticolo di analisi • Mar 17
Are Investors Undervaluing Afya Limited (NASDAQ:AFYA) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Afya fair value estimate is US$35.18 Current share price of...Articolo di analisi • Feb 10
Be Wary Of Afya (NASDAQ:AFYA) And Its Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...Articolo di analisi • Jan 21
Afya Limited (NASDAQ:AFYA) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Articolo di analisi • Jan 03
Should You Think About Buying Afya Limited (NASDAQ:AFYA) Now?
Afya Limited ( NASDAQ:AFYA ), might not be a large cap stock, but it saw a significant share price rise of 44% in the...Articolo di analisi • Dec 07
These 4 Measures Indicate That Afya (NASDAQ:AFYA) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Nov 02
Afya (NASDAQ:AFYA) May Have Issues Allocating Its Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Articolo di analisi • Sep 20
What Does Afya Limited's (NASDAQ:AFYA) Share Price Indicate?
While Afya Limited ( NASDAQ:AFYA ) might not be the most widely known stock at the moment, it saw a double-digit share...Articolo di analisi • Aug 17
Does Afya (NASDAQ:AFYA) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: È troppo presto per dire se i pagamenti dei dividendi di AFYA siano stati stabili, poiché hanno appena iniziato a pagare i dividendi.
Dividendo in crescita: È troppo presto per dire se i pagamenti dei dividendi di AFYA stanno aumentando, poiché hanno appena iniziato a pagare i dividendi.
Rendimento dei dividendi rispetto al mercato
| Afya Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (AFYA) | 5.0% |
| Fondo del 25% del mercato (US) | 1.4% |
| Top 25% del mercato (US) | 4.2% |
| Media del settore (Consumer Services) | 2.3% |
| Analista previsionale (AFYA) (fino a 3 anni) | 10.3% |
Dividendo notevole: Il dividendo di AFYA ( 5.03% ) è più alto rispetto al 25% inferiore dei pagatori di dividendi nel mercato US ( 1.39% ).
Dividendo elevato: Il dividendo di AFYA ( 5.03% ) è tra il 25% dei principali pagatori di dividendi nel mercato US ( 4.21% )
Distribuzione degli utili agli azionisti
Copertura degli utili: Grazie al suo payout ratio ( 41.4% ) ragionevolmente basso, i pagamenti dei dividendi di AFYA sono ben coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Grazie al suo cash payout ratio ( 26.5% ) ragionevolmente basso, i pagamenti dei dividendi di AFYA sono ben coperti dai flussi di cassa.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/07 10:02 |
| Prezzo dell'azione a fine giornata | 2026/05/07 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Afya Limited è coperta da 14 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Flavio Yoshida | BofA Global Research |
| Raphael Elage | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Valeria Parini | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |